Abstract
Background Breath acetone (BrACE) is an end product of ketone metabolism that is measurable by noninvasive breath ketone analyzers. We assessed the correlation between capillary blood β-hydroxybutyrate (BOHB) and BrACE in people with type 1 diabetes (T1D) during 14 days of outpatient care with and without dapagliflozin treatment and during supervised insulin withdrawal studies with and without dapagliflozin.
Methods In this randomized crossover study, participants completed 14-day two outpatient periods with or without dapagliflozin 10 mg daily. Each 14-day unsupervised outpatient period was followed by a one-day supervised insulin withdrawal study. Paired BOHB and BrACE measurements were obtained three times daily during outpatient periods, then hourly during supervised insulin withdrawal. The correlation between BrACE and BOHB was assessed by Spearman’s ρ.
Results Twenty people with T1D completed the study. During outpatient periods, BrACE and BOHB were moderately correlated (n=1425 paired readings; ρ = 0.41; 95% CI: 0.36 to 0.45; P < 0.0001). However, BrACE and BOHB were strongly correlated during insulin withdrawal (n=246 paired values, ρ = 0.81; 95% CI: 0.77 to 0.85). In ROC analysis, BrACE > 5 ppm demonstrated optimal sensitivity (93%) and specificity (87%) for detecting capillary BOHB ≥ 1.5 mmol/L. No serious adverse events occurred.
Conclusions In adults with T1D, measurement of breath acetone provides a noninvasive estimate of blood BOHB concentration. The correlation between BrACE and BOHB was suboptimal during unsupervised outpatient care, but was strong during supervised insulin withdrawal.
Trial registration: clinicaltrials.gov (NCT05541484)
Competing Interest Statement
A.M.Mc. is a current employee of Novo Nordisk Inc. At the time of the research A.M.Mc. was full-time faculty at Washington University in St. Louis. Contributions to this publication by A.M.Mc. were not on behalf of Novo Nordisk Inc. M.S. has received consulting fees from Eli Lilly and Neurocrine Biosciences, and receives grant funding to his institution from MBX Biosciences, Inc., Bayer HealthCare Pharmaceuticals Inc., Crinetics Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., and Mylan. J.B.M. has been a consultant for Bayer, Lilly, Mannkind, and Novo Nordisk; and has received grant funding from NIH, Novo Nordisk, Diamyd and Breakthrough T1D.
Clinical Trial
NCT05541484
Funding Statement
JDRF (2-SRA-2022_1190-M-B/P22-03211), National Institutes of Health grants UL1TR002345 (Washington University Institute of Clinical and Translational Sciences), including sub-award KL2TR002346 (ICTS Institutional Career Development Program), T32DK007120, P30DK020579 (Washington University Diabetes Research Center), and DK133995.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Washington University Human Research Protection Office (IRB #202206078)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Kai E. Jones Assistant Professor of Medicine, 660 S. Euclid, Campus Box 8127 St. Louis, MO 63110 314-561-2899, kaijones{at}wustl.edu; Max C. Petersen Assistant Professor of Medicine, 660 S. Euclid, Campus Box 8127 St. Louis, MO 63110 314-362-8450, max.p{at}wustl.edu; Alexander Markov 201 BJC St. Peters Dr St. Peters, MO 63376 636-916-9476, alexander.markov{at}bjc.org; Maamoun Salam Associate Professor of Medicine, 660 S. Euclid, Campus Box 8127 St. Louis, MO 63110 314-747-3979, salamm{at}wustl.edu; Petra Krutilova Assistant Professor of Medicine, 1725 W Harrison St Prof. Building Ste. 250 Chicago, IL 60612, 312-942-6163, Petra_krutilova{at}rush.edu; Alexis M. McKee Adjunct Faculty 660 S. Euclid, Campus Box 8127 St. Louis, MO 63110 314-273-4510, ammckee{at}wustl.edu; Kathryn L. Bohnert 660 S. Euclid, Campus Box 8127 St. Louis, MO 63110 314-273-3929, bohnertk{at}wustl.edu; Samantha Adamson Instructor in Medicine 4921 Parkview Place, 13th Floor Suite B, St. Louis, MO 63110 314-561-2903, sadamson{at}wustl.edu; Janet B. McGill Professor of Medicine 660 S. Euclid, Campus Box 8127 St. Louis, MO 63110 314-362-8681, jmcgill{at}wustl.edu
Funding sources: JDRF (2-SRA-2022_1190-M-B/P22-03211), National Institutes of Health grants UL1TR002345 (Washington University Institute of Clinical and Translational Sciences), including sub-award KL2TR002346 (ICTS Institutional Career Development Program), T32DK007120, P30DK020579 (Washington University Diabetes Research Center), and DK133995.
Conflict of Interest Disclosure: A.M.Mc. is a current employee of Novo Nordisk Inc. At the time of the research A.M.Mc. was full-time faculty at Washington University in St. Louis. Contributions to this publication by A.M.Mc. were not on behalf of Novo Nordisk Inc. M.S. has received consulting fees from Eli Lilly and Neurocrine Biosciences, and receives grant funding to his institution from MBX Biosciences, Inc., Bayer HealthCare Pharmaceuticals Inc., Crinetics Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., and Mylan. J.B.M. has been a consultant for Bayer, Lilly, Mannkind, and Novo Nordisk; and has received grant funding from NIH, Novo Nordisk, Diamyd and Breakthrough T1D.
Abbreviations
- (BrACE)
- Breath Acetone
- (BOHB)
- β-hydroxybutyrate,
- (T1D)
- Type 1 Diabetes,
- (SGLT2i)
- Sodium Glucose Cotransporter-2 inhibitor,
- (DKA)
- Diabetic Ketoacidosis,
- (VOC)
- volatile organic compound,
- (MDI)
- Multiple Daily Injections
- (CSII)
- Continuous Subcutaneous Insulin Infusion
- (HbA1c)
- Hemoglobin A1c
- (eGFR)
- Estimated Glomerular Filtration Rate
- (MOS)
- Metal Oxide Sensor
- (CGM)
- Continuous Glucose Monitor
- (BKA)
- Biosense Ketone Analyzer
- (CTRU)
- Clinical Translational Research Unit
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos